Factors of risk ateroscleróticos in mature patients with leukemia sharp mieloide

Authors

Keywords:

leukemia sharp mieloide, aterosclerosis, factors of risk.

Abstract

Introduction:
The leukemia sharp mieloide, constitutes the variety of more common leukemia in the adult. The aterosclerosis is a gradual process that arises from the birth and he/she goes progressing in successive decades of the life, until the appearance of clinical manifestations, illnesses multifactoriales or complex. Objective: To carry out a revision of the factors of risk ateroscleróticos related with the adult's leukemia sharp mieloide. Methods: He/she was carried out a revision of the literature in the databases of Pubmed, Scielo, Science Direct and the motor of search of Academic google, they took like references the articles published in the last 5 years. Results: The leukemia sharp mieloide represents 80% of the total of the adult's sharp leukemias and he/she has been proven that they constitute people's of the third age illnesses. Factors of risk that define presage in this entity exist. The aterosclerosis is an illness inflammatory progressive chronicle with high participation inmunitaria. The factor of good known and studied risk is the obesity, although other classic denominated factors of risk exist; important in the development of cardiovascular illnesses and cerebrovasculares; also ddel lifestyle and the psychological estrés. However, they seem to coexist other clinical situations and associate inflammatory markers or not to the classic factors that represent factors of risk aterogénicos. Conclusions: The factors of risk ateroscleróticos, as the age, the obesity, disfunción endotelial, systemic inflammation, hipertrigliceridemia, the metabolic syndrome, the factors homeostáticos, profile lipídico, the infections and the inflammation have influence in the complications of the patients with leukemia sharp mieloide.

Downloads

Download data is not yet available.

Author Biography

Yusaima Rodríguez Fraga

especialista de 2do grao en hematologia, profesor e investigador auxiliar, jefe de servicio de Hematologia Hospital clinico quirurgico hermanos Ameijeiras

References

1. Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, et al. American

Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid

leukemia in older adults. Blood Adv. 2020 [acceso 08/09/2021];4 (15):3528-49.

Disponible en: http://www.ioncol.com/upfile/down/202008281309.pdf

2. Mehranfar S, Zeinali S, Hosseini R, Mohammadian M, Akbarzadeh A, Feizi AHP.

History of leukemia: diagnosis and treatment from beginning to now. Galen Med J.

2017 [acceso

08/09/2021];6(1):12-22. Disponible en:

http://gmj.ir/index.php/gmj/article/view/702.

3. Cuba. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas

de Salud. Anuario Estadístico de Salud 2023. [acceso 08/09/2021]. Disponible en:

http://files.sld.cu/bvscuba/files/2020/05/AnuarioElectr%C3%B3nicoEspa%C3%B1ol-

2021-ed-2022.pdf.

4. Groarke EM. Clin Geriatric Med. 2019 [acceso 23/04/2025];35(3):285-93.

Disponible en: https://pubmed.ncbi.nlm.nih.gov/31230730/

5. American Cancer Society. Cancer Facts Figures 2021. Atlanta, GA: American

Cancer Society. 2021 [acceso 23/04/2025]. Disponible en:

https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-andstatistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf

6. American Cancer Society. Estadísticas importantes sobre la leucemia mieloide

aguda (AML).

2024 [acceso

20/05/2025]. Disponible en:

https://www.cancer.org/content/dam/CRC/PDF/Public/9064.00.pdf

7. Sekeres MA, Gordon G, Gregory A. American Society of Hematology 2020

guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Blood Adv. 2020 [acceso 23/04/2025];4:3528. Disponible en:

https://pubmed.ncbi.nlm.nih.gov/32761235/

8. Martínez-Acosta G, Rubio-Anguiano BL, López-Salvio YM. Aspectos geriátricos en

las neoplasias hematológicas. El Residente. 2017 [acceso 23/04/2025];12(1):4-17.

Disponible en: https://www.medigraphic.com/pdfs/residente/rr-2017/rr171b.pdf

9. Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, et al. American

Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid

leukemia in older adults. Blood Adv. 2020 [acceso 09/09/2021];4(15):3528-49.

Disponible en:

http://www.ioncol.com/upfile/down/202008281309.pdf

10. Díaz-Perera CA, Fernández G, Pérez EA. Papel de la epigenética en la

aterosclerosis y sus enfermedades consecuentes. Rev Cuban Salud Pública. 2022

[acceso 23/04/2025];48(Supl):e2673:15. Disponible en:

file:///D:/Users/bioestad.HHA/Downloads/admin,+a0_2673.pdf. 11. Raposeiras RS, Cordero A. La relación bidireccional entre el cáncer y la

ateroesclerosis.

Rev Esp Cardiol.

2019;72(6):487-92. DOI:

https://doi.org/10.1016/j.recesp.2018.12.011

12. Yu J, Li Y, Zhang D, Wan D, Jiang Z. Clinical implications of recurrent gene

mutations in acute myeloid leukemia. Exp Hematol Oncol. 2020 [acceso

23/04/2025];9(4):1-11. DOI: https://doi.org/10.1186/s40164-020-00161-7

13. Amacherla K, Well JA 4th, Bick AG. Clonal hematopoiesis and vascular disease.

Semin Immunopathol. 2022 [acceso 23/04/2025];44(3):303-08. Disponible en:

https://pubmed.ncbi.nlm.nih.gov/35122117/

14. Liesveld JL, Lichtman MA. Acute myelogenous leukemia. In: Williams'

Hematology. 10th ed. New York: McGraw-Hill; 2021. 2845-3017. [acceso

23/04/2025]. Disponible en:

https://accessmedicine.mhmedical.com/content.aspx?bookid=2962&sectionid=252

532651

15. Hoffman R, Benz EJ, Silberstein LE. Hematology Basic Principles and Practice.

ELSEVIER. 20217. DOI: https://doi.org/10.1016/C2013-0-23355-9

16. Intó X, Fanlo M, Esteve V, Millán J; Grupo de Trabajo Dislipemia Aterogénica.

Sociedad Española de Arteriosclerosis (SEA). Remnant cholesterol, vascular risk, and

prevention of atherosclerosis. Clin Investig Arterioscler. 2023;35(4):206-17.

DOI: https://doi.org/10.1016/j.arteri.2023.02.001

17. Belli C, Correa W, González J, Ferrari L, Dick H, Cranco S, et al. Influencia de los

hallazgos citogenéticos y moleculares en el pronóstico y respuesta a tratamiento de

pacientes con leucemia mieloide aguda. Rev Hematol. 2020 [acceso

23/04/2025];24(1):9-20. Disponible en:

http://revistahematologia.com.ar/index.php/Revista/article/view/267.

18. American Cancer Society. Cancer Facts Figures 2021. Atlanta, GA: American

Cancer Society; 2021 [acceso 23/04/2025]. Disponible en:

https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-andstatistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf

19. Sasaki S, Higashi Y, Nakagawa K, Kimura M, Noma K, Sasaki S, et al.

A low-calorie diet improves endothelium-dependent vasodilation in obese patients

with essential hypertension. American Journals Hypertensive. 2002;15(4 Pt 1):302-9.

DOI: https://doi.org/10.1016/s0895-7061(01)02322-6

20. Koskinas KC, Van Craenenbroeck EM, Antoniades C. Obesity and cardiovascular

disease: an ESC clinical consensus statement. European Heart Journal.

2024;45(38):4063-8. DOI: https://doi.org/10.1093/eurheartj/ehae508

21. Bu LL, Yuan HH, Xie LL, Guo MH, Liao DF, Zheng XL. New Dawn for

Atherosclerosis: Vascular Endothelial Cell Senescence and Death. Int J Mol Sci.

2023;24(20):15160. DOI: https://doi.org/10.3390/ijms242015160.

22. Song M, Wang H, Ye Q. Increased circulating vascular endothelial growth factor in

acute myeloid leukemia patients: a systematic review and meta-analysis. Syst Rev.

2020;9(1):103. DOI: https://doi.org/10.1186/s13643-020-01368-9. 23. Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and

atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct

Target Ther. 2022;7(1):131. DOI: https://doi.org/10.1038/s41392-022-00955-7

24. Liu F, Wang Y, Yu J. Role of inflammation and immune response in

atherosclerosis: Mechanisms, modulations, and therapeutic targets. Human

Immunology.

2023;84(9):439-49. DOI:

https://doi.org/10.1016/j.humimm.2023.06.002

25. Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ. et al. An inflammatory

state remodels the immune microenvironment and improves risk stratification in

acute myeloid leukemia. Nat Cancer. 2023 [acceso 23/04/2025];4(1):27-42.

Disponible en: https://www.nature.com/articles/s43018-022-00480-0#citeas

26. Custodio-Chablè SJ, Lezama RA, Reyes-Maldonado E. Platelet activation as a

trigger factor for inflammation and atherosclerosis. Cir Cir. 2020;88(2):233-43. DOI:

https://doi.org/10.24875/CIRU.19000725

27. Ikushima S, Ono R, Fukuda K, Sakayori M, Awano N, Kondo K. Trousseau's

syndrome: cancer-associated thrombosis. Jpn J Clin Oncol. 2016;46(3):204-8. DOI:

https://doi.org/10.1093/jjco/hyv165

28. Olivi M, Di Biase F, Lanzarone G, Arrigo G, Martella F, Apolito V. et al. Thrombosis

in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges.

Curr Treat Options Oncol. 2023 [acceso 23/04/2025];24(6):693-710. Disponible en:

https://link.springer.com/article/10.1007/s11864-023-01089-w

29. Rickles FR, Falanga A, Montesinos P, Sanz MA, Brenner B, Barbui T. Bleeding and

thrombosis in acute leukemia: what does the future of therapy look like? Thromb

Res. 2007;120(Suppl)2:S99-106.

DOI:

https://doi.org/10.1016/S0049-

3848(07)70137-8

30. López A, Rendón S, Barreto EE, Álvarez N, Acosta M. Índice predictivo para la

estratificación del riesgo de enfermedad tromboembólica venosa en pacientes con

hemopatías malignas. Acta Médica del Centro. 2021 [acceso 23/04/2025];15(4).

Disponible en:

https://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S2709-

79272021000400511&Ing=pt&nrm=iso&tlng=es

31. Li B, Xia Y, Hu B. Infection and atherosclerosis: TLR-dependent pathways. Cell

Mol Life Sci. 2020;77(14):2751-69. DOI: https://doi.org/10.1007/s00018-020-03453-7

32. Al Bander Z, Nitert MD, Mousa A, Naderpoor N. The Gut Microbiota and

Inflammation: An Overview. Int J Environ Res Public Health. 2020;17(20):7618. DOI:

https://doi.org/10.3390/ijerph17207618

33. Gurfinkel EP. Infección y aterosclerosis. Rev Cuban Med. 2001 [acceso

23/04/2025];40(4):273-87. Disponible en:

http://scielo.sld.cu/pdf/med/v40n4/med06401.pdf

34. Lusta KA, Poznyak AV, Sukhorukov VN, Eremin II, Nadelyaeva II, Orekhov AN.

Hypotheses on Atherogenesis Triggering: Does the Infectious Nature of

Atherosclerosis Development Have a Substruction? Cells. 2023;12(5):707. DOI:https://doi.org/10.3390/cells12050707 35. Wieczorek E, Ćwiklińska A, Jankowski M. Hypertriglyceridemia, a causal risk

factor for atherosclerosis, and its laboratory assessment. Clin Chem Lab Med.

2022;60(8):1145-59. DOI: https://doi.org/10.1515/cclm-2022-0189

36. Linton MF, Yancey PG, Davies SS, Jerome WG, Linton EF, Song WL, et al. The Role

of Lipids and Lipoproteins in Atherosclerosis. 2019 [acceso 23/04/2025]. Disponible

en: https://www.ncbi.nlm.nih.gov/books/NBK343489/

37. Rodríguez-Morales FM. Perfil lipídico en el diagnóstico de pacientes con

arteriosclerosis en América Latina. Journal Scientific MQ RInvestigar.

2024;8(1):2329-46. DOI: https://doi.org/10.56048/MQR20225.8.1.2024.2329-2346

38. Herrera González A, Peña Garcel Y, Soto Matos J, León Patiño EH. Utilidad de los

índices aterogénicos del perfil lipídico en el diagnóstico de aterosclerosis subclínica.

Rev Cuban Med. 2022 [acceso 15/11/2026];61(3):e2691. Disponible en:

https://revmedicina.sad.cu/index.php/med/article/view/2691

39. Finch ER, Smith SA, Yang W, Liu Y, Kornegay NM, Panetta JC, et al. Asparaginase

formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic

leukemia.

Pediatr Blood Cancer. 2020;67(1):e28040.

DOI:

https://doi.org/10.1002/pbc.28040.

40. Sanoval R, Gupta V. Hyperlipidemia in a case of acute lymphoblastic leukemia.

India J Cancer. 2019;56(2):180-1. DOI: https://doi.org/10.4103/ijc.IJC-724-18

41. Esfandbod M, Abazaria Tehrani M, Haghshomar M, Arya P, Shateri Amiri B,

Toogeh G, Keyhani M. Association between Perceived Stress and Neutropenia in

Patients with Leukemia under Chemotherapy. Int J Hematol Oncol Stem Cell Res.

2022;16(2):103-9. DOI: https://doi.org/10.18502/ijhoscr.v16i2.9203

42. Arrobas T, Guijarro C, Campuzano R, Rodríguez M, Valderrama JF, Perez A, et al.

Documento de Consenso para la determinación e informe del perfil lípido en

laboratorios clínicos españoles. Clin Investig Arterioscler. 2023;35(2):91-100. DOI:

Published

2026-11-17

How to Cite

1.
Rodríguez Fraga Y, Servando Roig Verdecia, Gutiérrez Izquierdo M. Factors of risk ateroscleróticos in mature patients with leukemia sharp mieloide . Rev Cubana Med [Internet]. 2026 Nov. 17 [cited 2026 Nov. 17];65. Available from: https://revmedicina.sld.cu/index.php/med/article/view/5167

Issue

Section

Review articles